trending Market Intelligence /marketintelligence/en/news-insights/trending/vbdmbd-cq4jw7rq1054amw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Catalyst Pharmaceuticals seeks US approval of autoimmune disorder treatment

Blog

JMP Securities is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

M&A rebound sparks optimism for near-term deal activity

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition


Catalyst Pharmaceuticals seeks US approval of autoimmune disorder treatment

Catalyst Pharmaceuticals Inc. is seeking approval in the U.S. for its Lambert-Eaton myasthenic syndrome treatment Firdapse.

Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder, most often characterized by muscle weakness of the limbs.

The U.S. Food and Drug Administration previously rejected the drug in 2016.

The submission to FDA is supported by the positive results of a phase 3 trial the company conducted under the regulator's special protocol assessment process. Firdapse demonstrated statistically significant improvements in arm and leg strength as well as face and neck muscle performance.